### Innovation for Health (IFH) Application Instructions

### For questions about applying, please contact:

|  |
| --- |
| [Seth Stutzman](http://Seth.T.Stutzman@jumpsimulation.org), Project Manager for Academic Collaborations at OSF HealthCare[Hanna Sperry](http://Hanna.M.Sperry@osfhealthcare.org), Project Manager for Innovation Academic Incubator (IAI) at OSF HealthCare[Brad Andersh](http://bja@bradley.edu), Director of Sponsored Programs at Bradley University[Michelle Eaton](http://meaton@bradley.edu), Associate Director of Sponsored Programs at Bradley University |
|  |

**Applications MUST be completed using** [**SM Apply**](https://osfhealthcare.smapply.io/prog/IFH) **and include ALL components listed below**

* If an item does not apply to your project, please clearly state why is it not applicable.
* Per [**Bradley University (BU) policy**](https://www.bradley.edu/academic/cio/osp/extramural-proposal/routing-process/), all proposals, contracts, and agreements for sponsored research must be internally reviewed before submission to an external organization. Therefore, on or before the IFH proposal deadline, the **BU project lead** must submit the project narrative, budget, and budget justification via DocSoup or OneAegis to ensure that all responsible parties agree to the submission. If requests for document modification and the BU approval process are not completed within five business days after the IFH proposal deadline, the proposal will be returned without review.

GENERAL INFORMATION

1. **Project Title** (This will be entered when creating the application)
2. **Executive Summary** (Up to 1,500 words)

State the application’s broad, long-term objectives and specific aims relevant to and how the project meets IFH’s goals. Provide a succinct and accurate description of the proposed work that should be able to stand on its own (separate from the application). This section should be informative to other people working in the same or related fields and understandable to a scientifically literate reader. Avoid both descriptions of past accomplishments and the use of the first person. The executive summary must include any additional information necessary for reviewers to evaluate the proposal (see evaluation criteria for more details). **Please be concise.**

PI INFORMATION

1. Provide the required information about the Principal Investigators (PI) (at least each one from BU and OSF), Co-Principal Investigator (if applicable), and any additional named collaborators (excluding students or postdoctoral fellows). Accurate contact details and institutional affiliations are necessary to ensure proper project documentation and communication. OSF HealthCare PIs must also confirm department head approval for time commitments. All PIs and Co-PIs must be added as collaborators in the SM Apply platform. It is recommended that all named collaborators be included as well.

RESEARCH PLAN

* If the project has unique aspects that do not fall within the categories below, do not hesitate to include additional information necessary to evaluate your proposal.

1. **Problem Statement and Contextual Significance**: Clearly define the clinical, operational, or public health problem your project addresses. Support the need with data, literature, or practice-based evidence. Explain why this issue is a priority for healthcare innovation and how it affects patient outcomes, access, cost, or quality, particularly within Central Illinois or the OSF HealthCare system.
2. **Specific Aims and Hypothesis (if applicable)**: List your specific aims as measurable objectives. These should reflect actionable steps your team will take to investigate, develop, implement, or evaluate a solution. If your project is hypothesis-driven, clearly articulate a central hypothesis and its scientific basis. If exploratory or developmental, state what you intend to demonstrate or achieve, and why that output matters.
3. **Innovation and Contribution to the Field:** What is novel about your approach, methodology, or application? Does it introduce a new tool, significantly enhance an existing process, or apply known solutions to a new clinical context or population? How does your work challenge prevailing practices or fill a critical translational gap?
4. **Approach and Study Design:** Describe your methodological framework, including study design, implementation strategy, population/sample, data sources, and analysis plan. Address feasibility, data collection and evaluation methods, and expected challenges. Include a discussion of limitations and mitigation strategies.
5. **Anticipated Outcomes and Translational Impact:** What outputs, deliverables, or outcomes will your project produce (e.g., validated tool, published findings, tested workflow, patient impact data)? How will this advance clinical practice, system operations, or health equity? What future research, scale-up, or commercialization pathways could follow from success?
6. Team Expertise and Institutional Readiness: Describe the expertise of the investigative team and relevant collaborators. Why is your team well-positioned to execute this work? What OSF infrastructure, community partnerships, or academic resources will support project success?
7. Plan to Engage Bradley University Students: Describe how current Bradley University students will be actively involved in the project in a meaningful way that will enhance their educational experience. It is highly recommended that students receive either monetary or credit hours for their contributions to the completion of the project. Note: If students will receive wages from this award, the Grantee must abide by the University’s policy that students cannot receive both compensation and course credit for the same effort.

ADDITIONAL INFORMATION

1. **Facilities/Equipment** (optional): If facilities or equipment are required that are not available in your laboratory or institution (e.g., use of a Simulation Center, simulation equipment, 3D printers, or VR/AR laboratories), please contact the Academic Collaborations team at [IAI@osfhealthcare.org](mailto:IAI@osfhealthcare.org)
2. **Plan for Securing Approvals from the Institutional Review Board (IRB)/Committee on the Use of Human Subjects in Research (CUHSR) or the Institutional Animal Care and Use Committee (IACUC)** (Required if applicable): While these approvals need not be in place at the time of submission, they MUST be secured before an award is executed. Failure to secure appropriate approvals may result in the award being rescinded.
3. **Background Technologies Statement:** The Background Technologies Statement provides information on any existing technologies, intellectual property, or proprietary assets relevant to the project. This may include patents, copyrights, trademarks, or trade secrets owned or licensed by the awardee. Understanding the background technologies is essential for ensuring compliance with legal and contractual obligations and avoiding potential conflicts of interest. This should be about a paragraph long, including a summary-level description of the disclosed Intellectual Property and focusing on its specific advantages over current technology. Additional information and related or supporting documents should be attached upon submission. This is the heart of the disclosure. The more information provided, the better equipped we will be to develop a protection strategy and evaluate commercialization potential. If you do not have any background technologies to disclose - please indicate that in this field.
4. **Future Funding and Intellectual Property Statement:** Given IFH awards are seed grants, discuss opportunities for future or matching funding from sources other than BU or OSF HealthCare, such as governmental or non-governmental organizations (e.g., private foundations, industry, etc.). Identify specific programs and submission deadlines. Discuss plans for submitting invention disclosures of intellectual property ideas to the OSF’s Office of Innovation Management (OIM) and the Bradley Office of General Counsel.
5. **Suggested Reviewers** (optional): Please list two to four (2-4) possible reviewers from both BU and the clinical institutions (OSF HealthCare and/or University of Illinois College of Medicine-Peoria). Provide the reviewers’ Name, Unit/Department, Institution, and Email address.

FINANCIALS

1. **Budget:** A detailed budget (use the current [template](https://osfhealthcare.smapply.io/protected/nr/7cbtQ/IFH_Budget_Template_Summer_25.xlsx)) must be entered in SM Apply.
2. **Budget Justification:** A separate budget justification/narrative (use the current [template](https://osfhealthcare.smapply.io/protected/r/FkmBTc_C-GJ6iD28zx8OmMjdxwM6qbz1XFuiwusn6cZP6K0Y2wiW4xOJCXxs1_zB_ORJiS7-6x8ZXnXzwgUF7g==/Budget_Justification_Help.pdf)) must be entered in SM Apply. The budget justification should describe why each line item is necessary for the project's success and include a brief explanation of how each amount was determined. Do not include the actual quotes, webpages, etc. An example of possible language to use for the budget justification can be found on Bradley’s Office of Sponsored Programs [website.](file:///Users/bja/Desktop/.%20%20https:/www.bradley.edu/offices/business/financial-services/policies-procedures/funds/budget-template.dot)
3. **See allowable and unallowable expenses below.**

ADDITIONAL INFORMATION FOR PHASE 2 PROJECTS

**Application Review Process:** Applications will be reviewed alongside other submissions in the funding cycle. Applications will undergo an additional review process for commercialization and external research opportunities. Phase 2 projects must demonstrate why they should be funded through a close-out report from your Phase 1 application and a clear translation pathway.

1. **Initial Goals and Objectives:** What were the primary goals of the first phase of your project? Provide an update on the status of each of the initial project objectives. (200-400 words)
2. **Results of Phase 1:** Summarize key findings or outcomes from Phase 1. (250-500 words)
3. Provide the names, dates, and locations of conferences or events where you have shared your results. (Bullet points, max 5 entries)
4. Provide full citations in APA format of published or submitted manuscripts. (Bullet points, max 5 entries)
5. List any patents or technology disclosures. (Bullet points, max 5 entries)
6. If your project is not selected for Phase 2, are you open to being directed to other potential funding mechanisms?

|  |
| --- |
| **Unallowable Expenses:** |
| Overhead/in-directs,tuition remission, routine costs (secretarial, supplies, etc.) that are a standard line item in institutional budgets**,** compensation for students who are not current, degree-seeking Bradley University students, and compensation for external research collaborators/presenters/co-authors. |

***\*Publication or Patent Application Costs:*** *Please do not include these expenses in the budget.* If funding is needed as the project develops, please contact Dr. John Vozenilek, Chief Medical Officer, Vice President for Innovation and Digital Health OSF HealthCare System or Dr. Christopher Jones, Vice President for Strategy and Innovation at Bradley University.

|  |
| --- |
| **Allowable Expenses**: |
| **Extra compensation for Project Leads:** All institutional extra compensation policies must be followed. At Bradley University, the appropriate policies are found in section II.B.3.b of the [Faculty Handbook](https://www.bradley.edu/academic/cio/senate/assets/docs/Faculty_Handbook.pdf) (the hourly rate for federally funded projects will be used) and in the [Exempt Employee Handbook](https://www.bradley.edu/offices/business/human-resources/assets/documents/ExemptEmployeeHandbook.pdf).  **Course/Duty Releases:** These are costs that will be incurred by the unit to cover the release from normal duties (e.g., teaching, clinical hours, etc.) Institutional approval must be obtained before the application is submitted. A letter of support from your supervisor must be included with the budget justification.  ***Undergraduate or Graduate Student Wages:*** *This is* compensation at an hourly rate for current, degree-seeking Bradley University undergraduate and graduate students, regardless of enrollment modality, to facilitate their engagement on the project.   * It is the expectation that students supported by grants will earn at least Illinois’ state minimum wage rate. * **Bradley University Policy:** Students cannot receive both compensation and course credit for the same effort.  Students may receive compensation if the duties are in addition to their course work as students. There must be a clear delineation between the course work and the duties being performed for compensation. Work duties versus course assignments must be specifically documented and there can be **no** overlap of responsibilities or the appearance thereof. |
| ***Consultants/contractual services:***These are services necessary for the proposed project, such as interpretation or translation services, transcription or annotation services, printing costs, use of equipment and instrumentation at another facility, or submission of samples for analysis by an outside vendor. |
| ***Participant Costs:*** These are costs related to involving human subjects in a study, such as participation incentives, fees for the purchase/use of a survey instrument or assessment tool, or other expenses that are directly related to the involvement of human subjects in an approved study. |
| ***Materials and Supplies:*** Items required to conduct the project (e.g., expendable materials and supplies that are less than $5,000). – It may not be used to replenish supplies necessary for other ongoing projects. |
| ***Travel Expenses:*** Includes registration fees and travel expenses necessary to present findings at conferences and professional meetings, as well as travel expenses required for the performance of the project (e.g., fieldwork, access to archives, service sites, etc.). |
| ***Capital Equipment or Instrumentation:***  Before capital equipment can be purchased using Innovation for Health (IFH) funding, the investigators must address the following items. (Capital equipment is defined as non-disposable items valued over $4,999.99.) When answering the questions, state plans for both during and after the award period.  Where will the device be housed?  How will access be granted to users from both institutions?  Who will maintain the device?  Who is responsible for repairs to the device?  Who will determine when the device is no longer viable and should be disposed of/recycled?  **Relevant information from the Innovation for Health (IFH) agreement**  Device means physical, electrical, or mechanical apparatuses, components, devices, equipment, instruments, samples, specimens, or tools.  Any Device(s) exchanged during the conduct of an IFH Project are owned by the providing Party. The transfer of a Device from one Party to the other under the terms of this Agreement shall not affect the providing Party's ownership interest in the Device(s). The recipient Party will maintain all Device(s) so that they are readily identifiable. The recipient Party shall use the Device(s) solely for the research purposes defined in the relevant Project Specification and shall not transfer, deliver, or otherwise release the Device(s) to a third party without the express prior written consent of the providing Party. Upon termination or expiration of a Project Specification, and at the instructions of the providing Party, the recipient Party shall return the Device(s) to the providing Party. In the event of damage or the failure of one Party to return the Device to the providing Party, the replacement cost of such Device shall be assessed the Party responsible for the damage or loss. |

**Terms of Awards**

### Each Party must identify the key personnel who will participate in an Innovation for Health (IFH) Project, with at least one Principal Investigator from each Party, who shall be joint Principal Investigators. In cases where only one Principal Investigator may be named (e.g., federal agency or grant), the parties will mutually agree on the Principal Investigator. Additional key personnel could, for example, include an appropriate combination of Co-Investigators, research scientists, and post-doctoral fellows. If any key personnel become unavailable to continue participating, the relevant Party will make every reasonable effort to arrange a substitution acceptable to the Primary Contact – OSF HealthCare (OSF) and the Primary Contact – Bradley University (BU). The Steering Committee shall have the right to reject any employee designated by a Party to work on an IFH Project. Other events, such as negative preliminary research results could demonstrate that the IFH Project should not or cannot be completed. The Principal Investigators are responsible for informing the Primary Contact - OSF and the Primary Contact - BU if it appears that it might not be appropriate or otherwise reasonably possible to continue the IFH Project or Project Specification. In such event, the Principal Investigators, and the Primary Contact - OSF and the Primary Contact - BU shall consult to determine the most appropriate course of action, which may include a modified scope of research or early termination of the IFH Project defined by a Project Specification. Final decisions rest with the Primary Contact - OSF and the Primary Contact - BU. If the decision results in funds originally budgeted to an IFH Project not being utilized for such a Project, then funds shall be deposited promptly back to the IFH Program.

#### The Principal Investigators from each Party (as applicable) will meet with their respective patent and technology commercialization representatives and the Intellectual Property Administrators at least quarterly to review existing details from any IFH Project relating to intellectual property. The Principal Investigators shall provide a semi-annual progress report to the Steering Committee, the format of which shall be developed by the Steering Committee.

#### A final report will be submitted by the Principal Investigators no later than one (1) month after the project end date listed on the project specification sheet. The final report will include all progress made on the project (with respect to project aims), intellectual property (IP) disclosures, summation of expenses, lessons learned, and any publications, papers, presentations, technologies or technique inventions, patient applications and/or licenses.

#### Unless otherwise specified, IFH Projects will last one year. One-year extensions may be granted dependent upon a progress review performed jointly by the Primary Contact - OSF and the Primary Contact - BU. An updated Project Specification Sheet will be generated summarizing the progress made, a revised budget, and outlined aims/goals to be reached should funding be extended.

#### Any Device(s) exchanged during the conduct of an IFH Project are owned by the providing Party. The transfer of a Device from one Party to the other under the terms of this Agreement shall not affect the providing Party's ownership interest in the Device(s). The recipient Party will maintain all Device(s) so that they are readily identifiable. The recipient Party shall use the Device(s) solely for the research purposes defined in the relevant Project Specification and shall not transfer, deliver, or otherwise release the Device(s) to a third party without the express prior written consent of the providing Party. Upon termination or expiration of a Project Specification, and at the instructions of the providing Party, the recipient Party shall return the Device(s) to the providing Party. In the event of damage or the failure of one Party to return the Device to the providing Party, the replacement cost of such Device shall be assessed by the Party responsible for the damage or loss.

## Use of Information

## The Parties each acknowledge that in executing an IFH Project and performing their respective roles pursuant to one or more Project Specifications, each may need to be exposed to and work with various confidential and proprietary information of the other Party. To assure protection of future Patent Rights and otherwise to preserve the confidences of the Parties and results of an IFH Project, each Party will advise its employees to use reasonable efforts to hold in confidence all proprietary information received from the other Party in connection with the IFH Project ("Confidential Information"); provided, however, that each Party may share Confidential information with third parties to the extent necessary to perform the IFH Project under terms consistent with this Agreement

## The obligations of nondisclosure and nonuse shall not apply to any information that:

##### as generally known to the public at the time of the disclosing Party's disclosure to receiving Party or becomes part of the public domain, through no action or inaction by the receiving Party;

##### a third party disclosed to the receiving Party without any apparent violation of the disclosing Party's confidential rights;

##### was known to the receiving Party prior to its receipt of the information;

##### is explicitly approved for release by written authorization of disclosing Party;

##### was developed by receiving Party independently of the activities in the IFH Project; or

##### is required to be disclosed by law, including civil or administrative procedure.

##### Upon the disclosing Party's request, the receiving Party will return all Confidential Information in the receiving Party's possession. One copy of the Confidential Information may be retained for legal archiving purposes. The obligations under this section shall survive for three years after the termination or expiration of this Agreement.

## To preserve the confidentiality and potential to seek patent protection or otherwise preserve IP rights, neither BU nor OSF shall publish any Data, IFH Project results, research, or any other material or information concerning an IFH Project, including in any scholarly or professional journals and shall not present the IFH Project results at professional meetings and conferences without first submitting it for review and comment to the Primary Contact - OSF and the Primary Contact - BU. The Primary Contacts shall have no less than fifteen (15) business days to provide such comments to both Parties, who will either revise the presentations to eliminate such disclosures or will delay publication for a limited period (thirty (30) business days or longer by written agreement) to allow for protection of IP related to any Project. In the event no comments are received in the review period, the presentation may proceed.

## The Parties will determine the authorship of publications in compliance with national research publication standards. In the event of joint authorship of manuscripts or materials by employees of OSF and BU concerning an IFH Project, the respective authors shall cooperate and share, as professionally appropriate, responsibility for preparation, review, and submission of the proposed manuscript or presentation materials. Any proposed manuscripts or presentation materials concerning the IFH Project will be furnished to the Primary Contact - OSF and the Primary Contact - BU at least thirty (30) business days prior to submission for the publication or public disclosure. The Primary Contact - OSF and the Primary Contact- BU shall respond within thirty (30) business days and if no response is forthcoming, publication may proceed. Upon notice that the proposed publication contains Confidential Information or enables disclosures of Intellectual property owned by a party, the Parties will either revise the publication to eliminate such disclosures or will delay publication for a limited period, not to exceed sixty (60) business days, to allow for preparation and filing of U.S. patent applications. If a joint publication is not submitted within twelve (12) months after the conclusion abandonment, or termination of an IFH Project, or after one Party confirms there will be no joint publication, the Parties may publish the results individually in accordance with the above review by the Primary Contact - OSF and the Primary Contact - BU. The Parties shall use reasonable efforts to arrange expedited reviews for abstracts, poster presentations, or other materials.

## To facilitate the protection of the Foreground, the Parties will encourage researchers to disclose potentially patentable discoveries to their respective technology commercialization offices in a timely manner.

## As scientifically and professionally appropriate, BU and OSF will acknowledge the contributions of the other Party in any resulting publication or public disclosure. The Parties will agree on the form and content of such acknowledgment prior to publication.

#### All disclosures, presentations, reports, collateral, and publications conveying any aspect of the IFH Projects or the results of an IFH Project shall identify both OSF and BU as well as IFH and provide further attribution and credit as determined by agreement of the Primary Contact - OSF and the Primary Contact - BU. The Parties will collaborate, where appropriate, and provide donor-appropriate recognition.

#### The Parties shall be respectful of the privacy of medical and personal information and shall at all times comply with all applicable federal and state laws governing the privacy of medical and personal information. OSF shall be ultimately responsible for Health Insurance Portability and Accountability Act (HIPAA) compliance related to its patient's protected health information, and accordingly, all awardees are required to disclose upon application, any activity that may include human subjects' research data. All primary awardee investigators will not be allowed to execute an IFH Project without written approvals from the ethical review board (e.g., Institutional Review Board) and other compliance bodies within OSF and/or BU.